Previous 10 | Next 10 |
6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancers No complement-mediated toxicities reported LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoin...
Agenus (AGEN) hit session highs, gaining 29%, partly popping after CNBC commentator Jon Najarian mentioned bullish call options for the oncology company.Najarian owns Agenus calls that expire on March 19.Veru Inc. (VERU) also gained 30% after a Najarian pitched the oncology com...
Agenus (AGEN) jumps 13% premarket following positive preliminary results from its Phase 1 trial of iNKT cell therapy in patients with moderate to severe symptoms of COVID-19. Preliminary data show that of the 4 patients dosed to date, 3 (75%) were extubated and released after treatm...
3 out of 4 intubated patients were discharged after treatment 2 out of 4 patients were extubated within 24 hours of dosing LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint ...
4 Penny Stocks To Watch With Increased Volume This Month Penny stocks were in direct focus on Wednesday. Partially thanks to surging prices in names like Express and GameStop, traders were seeking volatility. It was also a topic of conversation on countless financial outlets (obviou...
Today, we take our first in-depth look at a small biotech company called Agenus in nearly three years. The shares trade pretty close to where they were when our last article ran but there has been some recent news flow around this developmental concern. We account for recent event...
Agenus (AGEN) collaborates with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody, in combination with NLM-001, Nelum’s small molecule hedgehog inhibitor, and chemotherapy for first-line advanced pancreatic cancer. Under the terms of t...
LEXINGTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it has...
LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Je...
XOMA has built a large portfolio of drug royalties, over 65, with the potential to build a biotechnology business with high upside but limited and diversified downside protection. This royalty aggregator model has the potential to build a substantial balance sheet for XOMA, which will...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...